Analysts at Jefferies expect an eventful three months ahead for Tesla Inc (NASDAQ:TSLA), notably “more governance drama” at its annual general meeting (AGM) coming up on June 13.
At the meeting, shareholders will vote on whether CEO Elon Musk should receive an approximately $56 million pay package.
Flutter Entertainment PLC's (LSE:FLTR) recent share price dip is unjustified, according to analysts at investment bank Berenberg.
After hitting a peak of £175 earlier in the year, the price is now £148.40, though the shares are traded in the US primarily as Flutter completed its move from London to the New York stock exchange on Friday.
NatWest Group PLC's (LSE:NWG) £1.24 billion buyback of shares from the Treasury exceeded Peel Hunt analysts’ expectations.
They had initially expected just £1.1 billion in buybacks for the whole of 2023; today’s announcement has forced a rethink of the broker's full-year estimates.
Panmure Gordon has reaffirmed its 'buy' recommendation for BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF), maintaining a target price of 66p after the company's full-year results for 2023. The year saw significant advancements in BiVictriX's lead asset, BVX001, targeting acute myeloid leukaemia (AML), alongside progress in its broader pipeline.
Panmure flagged key operational achievements, including advancing BVX001 to investigational new drug-enabling studies and making headway with BVX002, aimed at solid tumours. The company's proprietary Bi-Cygni discovery platform expanded its library of cancer-specific fingerprints, allowing the targeting of diverse cancer types. BiVictriX aims to have two ready-for-clinic Bi-Cygni antibody-drug conjugates (ADCs) by 2026, the broker said.